Mibefradil

Drug Profile

Mibefradil

Alternative Names: Batenac®; Befral®; Cerate®; Mibefradil dihydrochloride; Posicor®; Quota®; RO 40-5967; Taxben®

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Cavion
  • Class Antihypertensives; Benzimidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrahydronaphthalenes; Vasodilators
  • Mechanism of Action Cell division modulators; DNA repair inhibitors; T type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Ovarian cancer; Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioblastoma; Glioma
  • Preclinical Ovarian cancer; Pancreatic cancer; Solid tumours
  • Market Withdrawal Angina pectoris; Hypertension
  • Discontinued Arrhythmias; Heart failure

Most Recent Events

  • 26 Sep 2016 Cavion plans a clinical trial for Brain cancer (In newly diagnosed)
  • 26 Sep 2016 Cavion plans a phase I trial for Glioblastoma (Newly diagnosed)
  • 30 May 2015 Cavion plans a phase I trial for glioblastoma (First-line therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top